Clinical Trial Update: A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating enzastaurin plus erlotinib in solid tumors and non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor
• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer, Malignant Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-13